Zdrowie i gospodarka · 18/08/2023
FDA Clears Path for Bortezomib Solution Concentrations
The FDA has determined that the 2.5mg/mL and 3.5mg/1.4mL concentrations of bortezomib solution were not withdrawn from sale due to safety or effectiveness concerns, allowing for potential approval of ANDAs for these formulations.